Description
EMPAMET XR 12.5/1000mg offers advanced, once-daily therapy for adults with type 2 diabetes. This extended-release tablet uniquely combines Empagliflozin 12.5mg, an SGLT2 inhibitor that helps kidneys excrete excess glucose, with Metformin Hydrochloride 1000mg (extended-release), which reduces glucose production and improves insulin sensitivity. The XR formulation enhances tolerability and allows for convenient once-daily dosing. Beyond powerful blood sugar control, EMPAMET XR 12.5/1000mg also significantly reduces the risk of cardiovascular death, hospitalization for heart failure, and progression of chronic kidney disease in eligible patients. Taken with a meal, it provides a comprehensive and well-tolerated approach to long-term diabetes management alongside diet and exercise.
